4U 1FUFSTCVSH $MVTUFS PG 1IBSNBDFVUJDBM BOE .FEJDBM *OEVTUSZ
ST. PETERSBURG – AN OPEN CITY
ST. PETERSBURG: A CENTER OF SCIENCE, INDUSTRY AND INVESTMENT
The third largest metropolitan city in Europe, St. Petersburg is an attractive place for living, conducting business, studying and spending holidays
The second by area and by significance city in Russia, a strategic center of the North-Western region, is contiguous with countries of the European Union
By right, St. Petersburg in the list of the world’s most attractive tourist destinations and one of the most beautiful European cities
Profitable geopolitical position, developed and diversified economy, effective transportation network
Its historical center, palaces and park ensembles have been included in the list of the objects protected as the world heritage by UNESCO
The sea port of St. Petersburg processes 65% of the entire exports of the country
Over 80% of historic landmarks belonging to the 18th-19th centuries are authentic and preserved in the original
27% - share of industry in the city economy Over 700 large and medium-sized industrial enterprises
The city of the White Nights, occupies the first place among Russian cities and one of the first in the world by the square of its water areas and the number of bridges
108,9% - industrial production index (Russia – 108,2%) One of the most actively developing regions in Russia, with an enormous investment potential (estimated by Standard & Poor’s, Fitch and Moody’s)
The most cosmopolitan, safe and tolerant city in Russia, St. Petersburg offers highly developed business, cultural and night life
Volume of foreign investment to the city in 2011 was USD 6.12 bln (+17% growth)
There are about 8 thousand sights of interest and more than a thousand cultural institutions which include museums, theatres, concert halls, exhibitions and cinemas, over 150 parks and gardens Over 260 festivals and contests are held annually
Huge human and intellectual resources: 60% of population is economically active Priority clusters of city economy:
Over 350 scientific and research companies and 90 higher educational institutions
• Automobile industry • Pharmacy and medical industry • Shipbuilding • Power machine building • IT • Radiology • Municipal economy
2
3
ST. PETERSBURG: INNOVATIVE INFRASTRUCTURE
NOVO�ORLOVSKOE SEZ SECTION
CITY CENTER
Priority sites for pharmaceutical manufacturing facilities and R&D centers location are «Pushkinskaya» industrial zone, Special Economic Zone sections: «Noidorf» and «Novo-Orlovskoe». The Government of St. Petersburg provides preferences and favorable environment for doing business to residents of these locations.
NOIDORF SEZ SECTION
ST. PETERSBURG SPECIAL ECONOMIC ZONE
ST. PETERSBURG SPECIAL ECONOMIC ZONE (SEZ) The technology development special economic zone is located in two sites: • «Noidorf» SEZ section (18,99 hectares) • «Novo-Orlovskoe» SEZ section (110,41 hectares) SEZ land use engineering budget (including Administrative and Business Center and technology transfer center) exceeds USD 47 mln.
«PUSHKINSKAYA» INDUSTRIAL ZONE
ADVANTAGES OF PROJECT IMPLEMENTATION IN THE SEZ: • Completed land use engineering
PULKOVO AIRPORT
The site is located in the South-West of St. Petersburg in Strelna settlement (Petrodvortsoviy district), in immediate access to the major highways (interchange with the Ring Road).
• Free customs regulations • No fees for power network plug-in
«PUSHKINSKAYA» INDUSTRIAL ZONE
• Opportunities for cooperation with R&D centers
The city provides infrastructure preparation of territories prospective for new pharmaceutical manufacturing facilities construction. Hence, volume of investment to «Pushkinskaya» industrial zone territory preparation is USD 13.3 mln.
• Simplified scheme of land plot providing
Land plot area – 18,2 hectares
2
1
Available land plot (5 hectares)
• to the city center – 40 minutes • to the «Pulkovo» airport (terminals 1, 2) – 20 minutes In 2011 the new R&D facilities in the Administrative and Business Center of «Noidorf» SEZ section were opened by:
Russia
4
14%
CJSC Pharm-Holding: developing, testing and introducing new pharmaceuticals;
SEZ
20%
CJSC BIOCAD: specializing in oncology/ hematology, gynecology/urology, neurology, viral infections, diabetes and cardiology.
15,5% 2,2%
Insurance fees
4
Transport accessibility:
34%
3
«NOIDORF» SEZ SECTION
Income tax
0%
Property tax
1,5%
0%
Land tax
0% Transport tax
Currently the CJSC BIOCAD manufacturing facilities are under construction at the «Noidorf» land plot to produce high-priced and widely used medicines from the VED (Vital and Essential Drugs) list to substitute their imports.
5
ST. PETERSBURG SPECIAL ECONOMIC ZONE
CLUSTER’S PARTICIPANTS: COMPANIES & KEY PROJECTS
Top pharmaceutical companies are placing their manufacturing facilities and R&D centers in the «Novo-Orlovskoe» SEZ section:
innovative licensed and generic oral solid medications
«Alkor Bio» Group was established in 1992. Today it is the major biotechnological holding company in the North-Western Russia incorporating 12 companies, which is among the top national manufacturers of reagents for enzyme immunoassay. The group is focused on:
import-substituting medications for oncology and HIV
• development, manufacturing and promotion of diagnostic kits for EIA & molecular genetic analysis; • private laboratory studies;
new generation innovative medications and generics to be applied in cardiology, dermatology, gynecology and dentistry
• development of cellular technologies with further introduction to clinical practice; • banking of hematopoietic stem cells from cord blood; • investment to innovative biotechnological projects.
«NOVO-ORLOVSKOE» SEZ SECTION The site is located in the Northern part of St. Petersburg (Primorskiy district) and is specified by the developed infrastructure: an interchange with the Ring Road is located nearby, with an access to the Western HighSpeed Diameter highway which will ensure fast transfer to the city center after completion of its construction. Transport accessibility: • to the city center – 40 minutes • to «Pulkovo» airport (terminals 1, 2) – 40 minutes
6
research and production of active pharmaceutical substances
blood-derived products
manufacturing equipment for diagnostic laboratories
200.000 reagents sets of over 60 positions are manufactured annually, including test-systems for hormonal diagnostics, cancer diagnostics, allergies, dangerous infectious diseases diagnostics, sets and software for DS prenatal screening. All diagnostics sets have been registered in Russia, most of them have received CE mark. The company has 7 R&D labs, 11 patents including cancer diagnostics, hepatitis C diagnostics, steam sells treatment methods against severe fractures, periodontitis, mental retardation.
www.alkorbio.ru
7
CLUSTER’S PARTICIPANTS: COMPANIES & KEY PROJECTS
RSI Syntez Ltd is a subsidiary of the Irkutsk pharmaceutical factory (Pharmasyntez, OJSC). The company was established to implement an investment project on building scientific and manufacturing facilities in Novo-Orlovskoe St. Petersburg Special Economic Zone section. The project is targeted to develop and produce innovative antitumoral medicines with planned annual turnover of at least USD 100 mln. Product range: antitumoral medicines in different dosage forms (pills, capsules, solutions, gels, lyophilizates). Today, a concept of the project is approved. At the first stage of construction, it is planned to assemble a line for aseptic fill of solutions equipped for lyophilization, with capsulating and tableting lines, implemented in isolation execution. Project assumes the R&D lab and training facilities for students of St. Petersburg high educational institutions. On some research works we are cooperating with several R&D centers in St. Petersburg. Design works and technological equipment will be provided by the European experts in construction and equipping of product lines for manufacturing based on high-toxic substances. Number of new workplaces: 200. Volume of investment: USD 700 mln. The project is scheduled to be completed by 2013 – 2014
www.pharmasyntez.com
8
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. On March 2011 AstraZeneca officially announced the launch of its Saint-Petersburg Predictive Science Centre (PSC) and became the first global pharmaceutical company to open its R&D facilities in Russia. The activity of AstraZeneca PSC will primarily focus on development and application of computational predictive modeling capabilities in all phases of drug discovery. Another area of interest will be the development of data analysis methods as well as software and systems; modeling and optimization of the pharmacological properties of potential drugs aimed to improve their safety and efficacy profiles. One more focus of the PSC will be the implementation of personalized medicine. The analysis of the clinical and high-throughput (e.g. genomics) data will help to develop and validate complex biomarkers identifying patients as well as to take into account genetic makeup of Russia population in order to optimize treatment strategies.
CJSC «Biocad» is the Russian biotechnological company founded in 2001. It is a fully integrated biotech company combining scientific research with manufacturing and marketing. Key activities of the company are focused on original and biosimilar/generic drugs development. The company was one of the four first members of the Neudorf Special Economic Zone section and pharmaceutical cluster of St. Petersburg. At the moment construction of a pharmaceutical complex Biocad 2.0 is in process which will create 500 new jobs. The first set of manufacturing facilities is scheduled to begin operations in 2013. The company is planning to develop and manufacture 32 costly and widely used drug products included into the VED (Vital and Essential Drugs) list, to substitute imported drugs in the following therapeutic areas of the Russian pharmaceutical market: oncology/hematology, gynecology/urology, autoimmune diseases, viral infections.
One of the company’s successful projects is «Organizing the pilot manufacturing of substances and drug preparations based on monoclonal antibodies, necessary for the production of costly, import-substituting products» which started in 2010 and was supported by the Presidential Commission for modernization and technological development of Russian economy. Within the scope of the project, the company is planning to develop 3 products – rituximab, bevacizumab and trastuzumab, which are currently at different stages of preclinical and clinical studies. At the end of 2011, a new laboratory (R&D center) was opened in the Administrative Center of Neudorf SEZ section, which specializes in the development of monoclonal antibodybased drugs. During the St. Petersburg International Economic Forum in June 2011 St. Petersburg Government, Pfizer corporation, CJSC «Biocad», and St. Petersburg State Chemical Pharmaceutical Academy signed an agreement for the development of an educational program to prepare and train specialists for the Russian pharmaceutical industry; the program kicked off with an opening of Academy’s scientific department in March 2012.
www.biocad.ru
www.astrazeneca.ru
9
CLUSTER’S PARTICIPANTS: COMPANIES & KEY PROJECTS
The project includes: • laboratories for new dosage forms development; • supply of modern equipment; • facilities for experimental works;
VERTEX OJSC is the Russian pharmaceutical company with 10-years history of success. Product range includes 108 positions, 65 are added to the VED (Vital and Essential Drugs) list and manufactured with the GMP standards. VERTEX is currently implementing an investment project to create the R&D and manufacturing facilities for development and production of innovative drugs and generics. New manufacturing will be located at the Novo-Orlovskoe St. Petersburg Special Economic Zone section.
Gem-Standart Ltd was established in 2011 to supervise the investment project on construction of R&D and manufacturing facilities for development and production of innovative medicines from the human blood plasma on the basis of nanotechnological solutions at the St. Petersburg Special Economic Zone (NovoOrlovskoe section).
• innovative technologies involvement; • highly experienced scientific and technical staff; • professional training.
The project will be fully completed by IV quarter, 2014. Volume of investment to the manufacturing construction exceeds USD 500 mln.
This will allow shortly and efficiently develop innovative technologies to receive innovative medicines from the human blood plasma.
Number of new workplaces: 220.
A unique for Russia technology of deep and full processing of precious human blood plasma will be created.
www.vertex.spb.ru
Geropharm Ltd is one of the leading Russian pharmaceutical manufacturers. Currently, Geropharm is processing construction of the new high technology industrial complex in accordance with GMP standards in Saint-Petersburg within St. Petersburg pharmaceutical and medical industry cluster development (manufacturing facilities are located in Pushkinskaya industrial area).
Project schedule: 2011 – 2015. Number of new workplaces: 150.
New manufacturing facilities will allow to produce original Russian medicines, innovative products as well as generics for the most important diseases treatment. Volume of investment at the first project stage is over USD 500 mln. Project is scheduled to be completed by 2014.
www.geropharm.ru
10
11
CLUSTER’S PARTICIPANTS: COMPANIES & KEY PROJECTS
epileptology centers, sleep laboratory, multifunctional policlinic department, radiosurgery centers Gamma Knife and Cyber Knife, comprehensive Cancer center. In 2011 over 900.000 patients were examined and 748 radiosurgery procedures completed on the basis of DTC IIBS centers. Diagnostic and Treatment Center of the International Institute of Biological Systems
This is an outstanding example of dynamic growth and a unique story of successful private investment in the Russian medicine.
Main activity of DTC IIBS is to provide affordable and high quality diagnostics and medical treatment services to its patients. Established in 2003, currently the company is an undisputed Russian leader in magnetic resonance tomography and radiosurgery.
The company is targeted to extend its MRI centers network to 70 by 2013 and to establish up to 5 new centers for positron emission tomography within next 2 – 3 years with total investment of over USD 70 mln.
Started from the first private MRI office in Russia, today DTC IIBS incorporates 58 MRI centers, multislice computer tomography and ultrasonic diagnostic cabinets, neurology and
Currently, a state-of-art Proton beam therapy centre in St. Petersburg is being designed. This large-scale project will be completed within 4 years (investment volume is estimated to exceed USD 140 mln).
www.ldc.ru
«Medical and Pharmaceutical Projects. XXI Century» is a non-commercial partnership operating in the sphere of development, production and circulation of medicaments and medical devices. It was founded in 2011 by a group of companies – participants of the pharmaceutical cluster in Saint-Petersburg as an effective tool for the development of medical-pharma branch and establishing market of quality and modern medical services. Main tasks of the partnership: • Participation in the development of the branch regulatory and legal framework; • Working out uniform rules and standards for the pharmaceutical market, methods of transition to GMP standards and manufacturers preparation to it; • Support of investment projects, promotion of the region investment attractiveness; • Legal backing (copyright, intellectual property, licensing); • International representation, monitoring of international projects. Today the partnership unites practically all the companies that implement production, research and educational projects in Saint-Petersburg. It is planned to create a self-regulatory organization (SRO) in the sphere of medicaments and medical devices development, manufacturing and circulation on the basis of the partnership.
www.21mpp.ru
12
Scientific and Technological Pharmaceutical Company «POLYSAN» Ltd was founded in 1992. «POLYSAN» manufactures four original drugs: Cycloferon, Cytoflavin, Reamberin and Remaxol. Currently, six more new original preparations are being developed at «POLYSAN», which are announced to start manufacturing within next four to five years. The company has been twice awarded the Russian Government Award for Science and Technology, the «Golden Mercury» Award for business achievements, and the Saint-Petersburg Government Award for top quality of products. The company’s pharmaceutical manufacturing facilities are located in Saint-Petersburg and certified by the European Union's GMP. Today, the second stage of construction is in process. Primary sales markets and regions: Russia, CIS, South-East Asia.
www.polysan.ru
13
CLUSTER’S PARTICIPANTS: COMPANIES & KEY PROJECTS
Samson-Med Ltd pharmaceutical company started its operations in 1937. Main activity of the company is producing medicines and substances by means of endocrine and enzymatic materials processing.
JSC «Pharmaceutical Factory of Saint-Petersburg» traces its history back to 1937. Currently, guideline of the company is production of drugs for asthma and COPD treatment.
The company has unique expertise starting from the D&D and technical regulations development to the industrial manufacturing of wide range of medicines (injectable preparations and infusion solutions) and biologically active substances.
In 2009 the company established the first Russian manufacturing of aerosolized medicines without ODS which were produced on state-of-art high-technologic equipment meeting the top international quality standards. Today the company produces «Beklospir®», which is the first Russian PANTONE 2995 C dosed aerosol inhaler with beclometasone dipropionate as an active ingredient. 7 more antiasthmatic medicines are proceeding registration now, after that demand of the Russian market of this medicines will be fully covered.
At the Pushkinskaya industrial area a project on a new full cycle manufacturing facilities construction for substances and drugs is being currently implemented. Project is scheduled to be completed by IV quarter, 2013 – II quarter, 2014. Volume of investment: USD 500 mln.
Pharm-Holding CJSC (a subsidiary of Geropharm Ltd) is the R&D company which is targeted to innovative medicines development. Mainly, company’s developments are focused to: • innovative peptide and genetically engineered medicines; • modern diagnostics systems; • improved generics. In December 2011 the unique Pharm-Holding R&D center in the Neudorf SEZ section was set up. Volume of investment to project is USD 4 mln. Number of new workplaces – 50.
Number of new workplaces: 400.
www.samsonmed.ru
14
www.galenopharm.ru
www.pharmholding.com
15
CLUSTER’S PARTICIPANTS: COMPANIES & KEY PROJECTS
to implement the joint plan with the Yaroslavl government to modernize cardiologic and therapeutic departments in the region, and launched together with Saint-Petersburg ChemicalPharmaceutical Academy the international educational project “Time for new ideas”. Cytomed medical and biological research and manufacturing complex is one of the first Russian pharma manufacturers for over 20 years at the market. Cytomed was among the first to support domestic biochemical and pharma R&D, manufacturing and promotion of original Russian products. Mainly, product range of Cytomed includes treatments applied in dermatology, urology, pediatry. Every medicine has his own registered brand name: Timogen, Prostatilen, Epitalamin, Cytovir. Manufacturing facilities of the company comply over 1200 sq m with units for creams, pills and ovules production. All treatments are manufactured of high-quality materials on the modern equipment meeting the GMP quality standards.
www.cytomed.ru
Today's MSD is a global healthcare leader working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. For more information, visit www.msd.com. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. About MSD in Russia In Russia, MSD is committed of developing innovative, first-in-class products, improving health and saving lives of Russian citizens. MSD in Russia is dedicated to science and scientific excellence, focusing on clinical research activities in the country. MSD products have been available in Russia for many years. In Russia, the company was recently renamed into MSD Pharmaceuticals LLC. About MSD in Emerging Markets In the Emerging Markets, MSD is currently ranked #5 by market share among multinational companies (IMS Health 2009); this ranking includes Asia Pacific, Latin America, Eastern Europe, Middle East and Africa. For MSD, Emerging Markets are defined as the following regions and countries: Asia Pacific, China, Latin America, Brazil, Eastern Europe and Middle East and Africa, including Russia. MSD's current portfolio and R&D focus are complementary to important disease areas with pressing public health issues in Emerging Markets: infectious diseases, vaccinations, cardiovascular disease, diabetes, women’s health and respiratory.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products.
Novartis and its predecessors have been active in Russia since XIX century, and today the company is one of the key players in the Russian pharmaceuticals market. Novartis currently employs over 2,400 associates in Russia across all business divisions.
www.novartis.ru
In December 2010 Novartis signed a Memorandum of understanding with Saint-Petersburg’s Government and announced a strategic investment program in Russia worth USD 500 million dollars over a 5-year period. This comprehensive partnership addresses three core areas which are local manufacturing, R&D partnerships and public health development in Russia. In June 2011 Novartis held a groundbreaking ceremony for new pharmaceutical manufacturing plant in Saint-Petersburg. Once completed and approved for commercial production, which is expected in 2014, the state of-the-art facility will use cuttingedge technologies to produce approximately 1.5 billion units per year. It will also be an attractive workplace for local talent, employing more than 350 highly qualified professionals who will have access to world-class training and development programs at Novartis. The new plant will meet GMP requirements (“Good Manufacturing Practice”). In 2011 Novartis continued
www.msd.com
16
17
CLUSTER’S PARTICIPANTS: COMPANIES & KEY PROJECTS
¾¥¤¹
ÂŤVital Development CorporationÂť JSC is one of the leading Russian developers and manufacturers of reagents kits for clinical diagnostics of various diseases – pancreas, kidneys, heart and other important systems diseases. The company also produces semi-automatic biochemical analyzers, water purifying stations for medical laboratories. Established in 2006, “Vital Development Corporationâ€? has become a joint stock company with annual turnover of USD 6 mln and 42 permanent employees by 2010.
Founded in 1995, ÂŤVAMÂť Group has focused its activities in pharmaceuticals. Its team has developed and patented an original scientific and technological platform to develop the new generation of drugs based on current achievements in molecular biology. The platform has been granted an entry into the registry of ÂŤMedical equipment and pharmaceuticalsÂť project group under the Presidential Commission for Modernization and Technological Development of the Russian Economy.
“Vital Development Corporation� is focused on promotion at the world market of its products meeting all standards of quality. A key priority for the company in short-term period is R&D in laboratory diagnostics. Within this line, the company became a resident of the St. Petersburg Special Economic Zone (Novo-Orlovskoe section) in 2009. By the end of 2012, the company is intended to set up the R&D and manufacturing facilities “Vital� (two manufacturing buildings and one administrative building) of 9 000 sq m in total with over 100 new workplaces.
The first breakthrough products recognized by the international scientific community and registered in Russia were drugs for socially significant diseases treatment - tuberculosis and viral hepatitis GlutoximÂŽ and MolixanÂŽ.
Nowadays, “Vital Development Corporation� is a member of the Technical and Implemental Companies Association. The company’s investment program is estimated at USD 15 mln by 2014, its strategic lines are R&D, manufacturing facilities in the SEZ construction and promotion at the emerging markets (Asia, Africa and Middle East).
www.vital-spb.ru
18
2593 C 423 U
New generation of drugs development by the “VAM� Group provide pharmacological solutions to affect human innate defense mechanisms. Threat of antibacterial and antiviral agents therapeutic effectiveness loss (agents to treat hepatitis C & B virus, flu, acute respiratory and intestinal virus infection contaminations, tuberculosis, a purulent infection contamination and others) caused active research of this issues being carried out by top pharmaceutical companies and R&D centers.
After Head of the World Healthcare Organization Dr Margaret Chen, today humanity faces a level of drug resistance which may mean ÂŤthe end of medicine as we know itÂť. Now we enter ÂŤthe post-antibiotic eraÂť. According to experts, a problem of modern microorganisms drug resistance to the etiotropic agents will be solved by the new group of drugs called innate defense regulators - IDR. Today GlutoximÂŽ is the only registered and marketed drug from this new therapeutic group which effectively fights a drugs resistance problem.
www.glutoxim.ru
19
WELCOME TO ST. PETERSBURG
Vadim Vlasov
President, Novartis Group of Companies in Russia
«Making the decision to invest in localization in Russia, we have chosen St. Petersburg as the city fullly meets the demands of the investors. Such factors as local qualified staff, strong R&D basis, support of the city government and special preferences for the investors in the region are important stimulus for localization and conduction of business»
Dmitriy Morozov, CEO, BIOCAD CJSC
«The technological and manufacturing breakthrough in our sector can happen only in St. Petersburg which is the best location in Russia for knowledge-intensive manufacturing development. To tell about pharmaceutical production, benefits are multiplied by attractive tax and customs incentives of the Neudorf Special Economic Zone section: facilities construction within the cluster will allow our company to save up to 45% of budget, since the infrastructure is being provided by the local administration. Pharmaceutical cluster truly exists. First, the companies constantly communicate with each other, establishing channels for cooperation. Second, the higher education institutions are actively involved in this activity. Shared scientific base and manufacturing cooperation leads to synergies, when two times two is more than four, which means the goals of the cluster are being achieved»
20
Petr Rodionov,
Mark Balazovskiy,
Director, Geropharm Ltd
CEO, PHARMA VAM OJSC
«We are confident that the activities of our Russian Predictive Science Centre will help not only to accelerate the development of safer and more effective medicines but also to create a professional culture and educational basis for R&D development in Russia. This will contribute Russian patients’ health and life quality improvement»
«Saint-Petersburg is a definitely one of the most perspective Russian regions to develop innovations and to create strong industrial and scientific basis. All factors provided by the region contribute to that: favorable investment climate, well-developed infrastructure, highqualified experts. Efficient partnership between cluster participants and support of the city government are also very important»
«St. Petersburg is not my choice, but my motherland. Everything I could achieve in my life is connected with it. Here the ideas were born and the results to create new generation of medicines were achieved. To bring innovative, perfect solutions was the basic idea of the city’s founder as a keystone for its development»
Nenad Pavletic,
Jeffrey Kemprecos,
Alexandr Borisov,
Vitali Proutski,
Head of R&D Information, AstraZeneca Russia, Head of Saint-Petersburg Predictive Science Centre
President, AstraZeneca Russia
«There is no doubt that the Northwest region is one of the most prospective in Russia. The intellectual capacity and great scientific base are real advantage for attracting investments into R&D development. Accordingly, AstraZeneca has become a long term partner of St. Petersburg in pharmaceutical sector modernization and announced its intention to establish R&D Predictive Science Centre in the region»
Public Affairs Lead EEMEA, MSD International GmbH
«In recent years, the global medicines discovery effort is diversifying to regions outside the historical core. While it has been documented that talented individuals from Eastern Europe, the Middle East and Africa have made important contributions in the historical core countries accounting for most medical breakthroughs, a new trend is emerging whereby countries on the near periphery are demonstrating an increasing interest in developing the innovative medicines sector, in countries as diverse as Morocco, Algeria, Saudi Arabia, the UAE, Turkey and Russia. The private sector is evaluating these opportunities, and while there are still many reasons for caution, is capitalizing on opportunities in some countries»
Director General, STPF «POLYSAN», Ltd
«Saint-Petersburg is a fast growing and developing city which values the treasures kept by our people and streets. We are pleased that this development processes are now applied to the pharmaceutical industry. There are new projects and interesting offers among them. All these give us the opportunity to build the longterm business plans and solve the complex tasks quickly. We greatly value the support, provided by the St. Petersburg City Government to all, what is of great importance and interest to us»
21
WELCOME TO ST. PETERSBURG
Evgeniy Elin,
Alla Shenger,
Vladimir Yurgin,
Alexander Semenov,
«Our pharmaceutical company has been working in St. Petersburg for many years, since then we have formed a clear vision of all regional benefits. Joining to the St. Petersburg pharma cluster in 2010 gives us opportunities for various preferences and grants to build new pharmaceutical manufacturing facilities, and opens up ways to establish new partnerships with the other cluster’s participants »
«For people it is very important to reach high-quality medicines. Cooperation with the European design companies and equipment manufacturers allows us to offer innovative solutions vital for the Russian market»
«Thanks to its unique investment climate, high human and scientific capacity, together with the governmental support aimed to develop pharmaceutical industry, St. Petersburg has recently become a pharmaceutical capital of Russia. That is why Vertex decided to create its manufacturing facilities in St. Petersburg, since this allows us to contribute to the development of the region as well as to the Russian pharmaceutical industry»
Dmitriy Polyntsev,
Alexander Harchenko,
Tamerlan Balaev,
Dmitriy Chagin,
«Despite that products for hormonal, cancer and allergy diagnostics manufactured by our holding company have analogues worldwide, a process of their creation itself is absolutely innovative. We develop new technologies so our products are different from what is represented at the market today. First, we can not be compared with domestic manufactures; our competitors are large international companies. Second, we make truly innovative products and technologies that have no analogues in our country»
«St. Petersburg was always attractive for us, we even discussed partnership opportunities with Paster Institute, but only today situation is the most favorable: expertise in our own manufacturing facilities construction, financial opportunities supported by the Special Economic Zone preferences, high-trained human resources of the Northern capital, good transport access and simply gorgeous architecture and landscapes! We strive to reduce gap of domestic blood agents in the North-Western Russia»
«St. Petersburg is the most attractive region for pharmaceutical manufacturers thanks to its serious scientific potential, especially St. Petersburg Chemical & Pharmaceutical Academy with the only department in Russia specialized in pharma manufacturing experts’ training, a technological university and several medical high educational institutions. There is also an efficient system of pharmaceutical industry support from the city government»
«Medical and Pharmaceutical Projects. XXI century» non-commercial partnership is a reflection of the national idea of «creation for sake health». All the members of our partnership are friends on the same page»
Chairman, Committee for Economic Development, Industrial Policy and Trade «We are implementing a high priority national project aimed to improve pharmaceutical and medical industry in Russia, increase its competitiveness to secure innovative and high-quality medicals of national origin for our people. Having stressed great efforts and our will to achieve this, we are offering investors best opportunities to enter the market and to do business in St. Petersburg»
President, Alkor Bio Group
22
Director, Samson-Med, Ltd
Director General, Immuno-Gem OJSC
General Director, RCI Synthez
Director General, Pharmaceutical Factory of SaintPetersburg
CEO, VERTEX OJSC
Director, “Medical and Pharmaceutical Projects. XXI century” NCP
23
*OWFTU JO TVDDFTT *OWFTU JO 4U 1FUFSTCVSH
JOWFTUTQC!DFEJQU TQC SV
XXX DFEJQU TQC SV